In the last week, the market has stayed flat, but over the past 12 months, it has risen by 20%, with earnings forecast to grow annually by 18%. While penny stocks might seem like a term from a bygone era, they continue to offer intriguing opportunities for investors seeking affordability and growth potential. By focusing on smaller or newer companies with strong financials and solid fundamentals, investors can uncover promising options in this often-overlooked segment of the market.

Here we highlight a subset of our preferred stocks from the screener.

Commercial Vehicle Group (CVGI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Commercial Vehicle Group, Inc. supplies systems, assemblies, and components to the vehicle and electric vehicle markets across North America, Europe, and the Asia-Pacific region with a market cap of $155.80 million.

Operations: The company generates revenue through three main segments: Global Seating ($288.35 million), Global Electrical Systems ($210.18 million), and Trim Systems and Components ($152.18 million).

Market Cap: $155.8M

Commercial Vehicle Group, Inc. has recently been added to multiple Russell indices, which may increase its visibility among investors. Despite being unprofitable with a negative return on equity of -12.55%, the company has shown improved financial health by reducing its debt-to-equity ratio from 150.5% to 71.4% over five years and maintaining short-term assets that exceed both short-term and long-term liabilities. However, interest payments are not well covered by earnings, indicating potential financial strain. The company's stock is trading at a significant discount compared to fair value estimates, though it remains highly volatile over recent months.

Pulmonx (LUNG)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Pulmonx Corporation is a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema, with a market cap of $62.51 million.

Operations: The company's revenue is derived entirely from its medical products segment, totaling $88.55 million.

Market Cap: $62.51M

Pulmonx Corporation, with a market cap of US$62.51 million, has faced challenges as it was recently removed from several Russell indices but added to the Russell 3000E Value and Microcap Value Benchmark. The company reported a first-quarter revenue of US$20.59 million for 2026, down from the previous year, while maintaining short-term assets that cover both short and long-term liabilities. Despite being unprofitable with a negative return on equity of -116.28%, Pulmonx holds more cash than debt and is trading at good value compared to peers, though insider selling has been significant recently.

Marchex (MCHX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Marchex, Inc. is a conversation intelligence company that offers conversational analytics and related solutions across the United States, Canada, and internationally, with a market cap of $77.91 million.

Operations: The company generates revenue from its Conversational Analytics and Related Solutions segment, which amounted to $44.64 million.

Market Cap: $77.91M

Marchex, Inc., with a market cap of US$77.91 million, recently experienced removal from several Russell indices, reflecting potential challenges in market perception. Despite being unprofitable with a negative return on equity of -17.25%, the company maintains strong liquidity, as short-term assets exceed liabilities and it remains debt-free. Revenue for Q1 2026 was US$10.62 million, showing a slight decrease from the previous year but improved net loss figures indicate reduced losses over five years at 19.1% annually. The launch of its Agent Behaviors solution underscores Marchex's strategic focus on enhancing sales execution through AI-driven insights and analytics solutions.

Key Takeaways

• Access the full spectrum of 325 US Penny Stocks by clicking on this link.
• Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.